Notice to convene Evaxion’s Annual General Meeting
Evaxion (NASDAQ: EVAX) has convened its Annual General Meeting for April 16, 2026 at 14:00 CET to be held at the company's offices in Hørsholm, Denmark.
Rhea-AI Summary
Evaxion (NASDAQ: EVAX) has convened its Annual General Meeting for April 16, 2026 at 14:00 CET to be held at the company's offices in Hørsholm, Denmark. The agenda and meeting materials are available on the company's investor website, and investor contact details are provided for further questions.
Positive
- None.
Negative
- None.
Details
News Market Reaction – EVAX
In the Mar 19 session, EVAX gained 5.82%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- AGM date
- April 16, 2026
- Scheduled date of Evaxion’s Annual General Meeting
- AGM time
- 14.00 CET
- Scheduled start time of the Annual General Meeting
- Office address number
- 5F, 2970
- Street/unit and postal code of Evaxion’s office hosting the AGM
- IR phone
- +45 53 54 82 96
- Investor Relations contact number for AGM-related inquiries
Historical Context
-
Full-year 2025 results with stronger finances and major partnership wins.
-
Slight delay to 2025 annual report filing due to technical vendor issues.
-
Announcement of date and call details for full-year 2025 results.
-
Expansion of AI-Immunology™ into autoimmune with cash runway unchanged.
-
Planned 2026 milestones presentation at Biotech Showcase conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces that its Annual General Meeting is convened to be held on April 16, 2026, at 14.00 CET.
The meeting will be held at the company’s offices, Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark.
The agenda and proposals can be found on Evaxion’s website, along with other materials:
www.evaxion.ai/investors/events-presentations/annual-general-meeting-2026/
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.
With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development
We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.
For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.